Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/0183dddd-a9ed-483e-823c-fabda555be47/
RPGLIFE
RPG Life Sciences LimitedSnapshot 2026-06-07 · 0.0w · Fresh
Strategy Eligibility
1 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
12-1 16%
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
24.0%ile
P/E
18.3×
P/S
5.3×
P/B
5.9×
E/P
0.0547
FCF Yield
-0.003
EBITDA/EV
0.076
SH Yield
0.000
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
76.00000000
/100 — 1=cheapest
VC2 (Trending Value)
74.00000000
/100
VC3 (Buyback)
76.00000000
/100
Negative FCF yield (-0.3%) — the business is currently cash-consumptive.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
66.0%ile
ROE
0.323
ROA
0.247
Net Margin
0.293
Op Margin
0.167
GPA
0.548
Current
3.48
F-Score
3/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.083
Earn Growth
-0.371
Stability
0.869
lower=better
Accruals
0.175
lower=better
5yr Consist
No
ROE of 32% is exceptional. Accruals ratio of 0.175 is elevated — earnings quality may be lower than headline numbers suggest.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
76.0%ile
6M Return
-1.8%
12M Return
1.9%
12-1 Mom
16.2%
Risk-Adj
0.60
Vol 252d
27.1%
Vol 60d
64.0%
↑ Expanding
Max DD 12M
-26.2%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
Near-term vol (64%) is expanding vs long-term (27%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.45
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare
· 160 peers
Sector Value %ile
47.2%
Sector Quality %ile
47.8%
P/E z-score
-0.23
P/B z-score
0.08
Sector Avg OS
43.7%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
| Symbol | Name | OS | Value | Quality | Momentum |
|---|---|---|---|---|---|
| NATCOPHARM | 98.0% | 88.0% | 87.0% | 81.0% | |
| UNIVPHOTO | 97.0% | 86.0% | 74.0% | 94.0% | |
| LINCOLN | 97.0% | 88.0% | 80.0% | 81.0% | |
| STAR | 96.0% | 73.0% | 91.0% | 91.0% | |
| VENUSREM | 96.0% | 68.0% | 94.0% | 99.0% | |
| HALEOSLABS | 95.0% | 82.0% | 77.0% | 81.0% | |
| AUROPHARMA | 94.0% | 71.0% | 84.0% | 87.0% | |
| SPARC | 93.0% | 72.0% | 86.0% | 83.0% |
Factor Interactions
Earnings Quality Concern
ROE looks strong (32%) but high accruals (0.175) suggests earnings are accrual-heavy, not cash-backed.
Volatility Expanding
60-day vol (64%) significantly exceeds 252-day (27%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
D
37.5% avg (7 factors)
Quality
A
79.2% avg (7 factors)
Momentum
D
41.4% avg (4 factors)
Risk
B
71.6% avg (1 factors)
High quality business commanding a premium price. The market recognises the quality — returns from here depend on continued fundamental execution. Momentum is weak, suggesting the market isn't yet buying this thesis. Patience required.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Factor Persistence1 snapshots
| Factor | Current | Streak | Trend | Spark |
|---|---|---|---|---|
| OS Composite | 0.450 | —0 | — | |
| Value %ile | 0.240 | —1 | — | |
| Quality %ile | 0.660 | —0 | — | |
| Momentum %ile | 0.760 | —1 | — | |
| F-Score | 3.000 | —1 | — | |
| Confidence | 0.939 | —1 | — | |
| Volatility | 0.271 | —0 | — |
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
18.27
Earnings Yield (E/P)
0.0547
Price / Sales
5.34
Price / Book
5.91
Price / Cash Flow
63.28
FCF Yield
-0.3%
EBITDA / EV
7.6%
Sales Yield (1/P·S)
0.1942
Shareholder Yield
Div + net buyback / mktcap
0.0%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
32.3%
Return on Assets
24.7%
Net Margin
29.3%
Operating Margin
16.7%
Gross Profit / Assets
Novy-Marx GPA
54.8%
Current Ratio
3.48
Accruals Ratio
(NI-OCF)/Assets — lower=better
0.175
MomentumPrice trend strength over different horizons
6M Return
-1.8%
12M Return
1.9%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
16.2%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
0.60
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
8.3%
Earnings Growth (YoY)
-37.1%
Earnings Stability (CV)
Lower = more stable
0.869
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
3
Dividend Yield
0.0%
Buyback Yield
0.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
76
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
74
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
76
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity